References
- Chow, S. C. (2013). Biosimilars: Design and Analysis of Follow-on Biologics. New York, NY: Chapman and Hall/CRC Press, Taylor & Francis.
- Chow, S. C. (2014). On assessment of analytical similarity in biosimilar studies. Drug Designing 3:119. doi:10.4172/2169-0138.
- Chow, S. C. (2015). Challenging issues in assessing analytical similarity in biosimilar studies. Biosimilars 5:1–7.
- Chow, S. C., Liu, J. P. (2008). Design and Analysis of Bioavailability and Bioequivalence Studies, 3rd ed. New York, NY: Chapman Hall/CRC Press, Taylor & Francis.
- Christl, L. (2015). Overview of the regulatory pathway and FDA’s guidance for the development and approval of biosimilar products in the US. Presented at the Oncologic Drugs Advisory Committee meeting, January 7, 2015, Silver Spring, MD.
- FDA. (2003). Guidance on Bioavailability and Bioequivalence Studies for Orally Administrated Drug Products – General Considerations, Center for Drug Evaluation and Research, the US Food and Drug Administration, Rockville, MD.
- FDA. (2015). Scientific considerations in demonstrating biosimilarity to a reference product. The United States Food and Drug Administration, Silver Spring, MD.
- Tsong, Y. (2015). Development of statistical approaches for analytical biosimilarity evaluation. Presented at DIA-FDA Statistics Forum, Bethesda, MD, April 19–22, 2015.
- Yu, L. X. (2004). Bioinequivalence: concept and definition. Presented at Advisory Committee for Pharmaceutical Science of the Food and Drug Administration, April 13–14, Rockville, MD.